Engitix Expanded its 2020 Collaboration and License Agreement with Takeda to Develop New Anti-Fibrotic Therapies for Inflammatory Bowel Disease
Shots:
- Engitix to receive up front with near-term fees based on the confirmation & functional validation of selected targets, ~$300M in preclinical, development, regulatory & commercial milestones along with royalty on sales of commercialized products
- Takeda to get exclusive rights to develop & commercialize the product generated against validated targets. The companies will validate the targets & preclinical development of therapies in IBD using Engitix’s ECM platform
- The agreement builds upon the 2020 agreement to develop novel therapies for advanced fibrotic liver diseases. The new agreement combines Engitix’s ECM platform & Takeda’s expertise in gastroenterology R&D and commercialization
Ref: Businesswire | Image: Businesswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
